Award
National Cancer Institute 5R01CA276286-04
Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance
Recipient
University of Connecticut
Award Amount
$552,755.00
Ceiling
$552,755.00
Awarded
February 13, 2026
Identifier
5R01CA276286-04
Award for research on Immunotype-1 as a biomarker for resistance to immune checkpoint blockade in cancer, funded by the National Cancer Institute.
Description
The project focuses on identifying a biomarker called Immunotype-1 (IT-1) for resistance to immune checkpoint blockade (ICB) in cancer treatment. The project aims to characterize immune cells, determine clinical outcomes, and assess response to therapy across cancer types. The project involves clinical data, immune profiling, and biomarker validation. The project duration is from July 10, 2023, to December 31, 2028.